Due to strong sales in the second quarter, including better-than-expected organic growth at Bausch + Lomb, Bausch Health raised its adjusted Ebitda guidance for the full financial year. The Canadian group - previously called Valeant Pharmaceuticals - now expects it to be in the range of $3,200 to $3,350 million, ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
To continue reading this article register now.